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Low copy number (CN) of the FCGR3B gene reduces FCGR3Bmembrane expression on neutrophils and results in clearance of a
smaller amount of immune complex. We investigated FCGR3B CN in relation to the clinical phenotype in a Caucasian SLE cohort
(𝑛 = 107). FCGR3BCNwas determined by three different qPCR parameter estimations (Ct−, Cy0, and cpD1) and confirmed by the
FCGR2C/FCGR2A paralog ratio test. Clinical and serological data were then analyzed for their association with FCGR3B CN. Low
FCGR3B CN (<2) was more frequent in SLE patients than in healthy controls (𝑛 = 162) (20% versus 6%, OR 4.15, 𝑃 = 0.003) and
associated with higher disease activity scores (SLEDAI 10.4 versus 6.1, 𝑃 = 0.03), lupus nephritis (LN) (25 versus 5%, 𝑃 = 0.03), and
increased levels of antibodies against dsDNA (81 versus 37 IU,𝑃 = 0.03), C1q (22 versus 6 IU,𝑃 = 0.003), and ribosomal P (10 versus
5 IU, 𝑃 = 0.01). No such associations were seen with antibodies against extractable nuclear antigens or high FCGR3B CN (>2). In
multivariate analyses, LN was independently associated with anti-C1q-Ab levels (𝑃 = 0.03) and low FCGR3B CN (𝑃 = 0.09). We
conclude that the susceptibility for LN in patients with low FCGR3B CN is linked to increased levels of pathogenic autoantibodies.
1. Introduction
Systemic lupus erythematosus (SLE) is a severe autoimmune
disease that causes a wide spectrum of clinical and serological
abnormalities [1].The characteristic production of antibodies
against nuclear and cytoplasmic antigens, which normally
are shielded from the immune system, results among others
from defective clearance of apoptotic material [2, 3]. Immune
complexes containing autoantibodies and nuclear antigens
(IC) play a central role in renal inflammation, and depending
on their interaction with activating and/or inhibitory FCgR
can lead to complement activation, cytokine release, and
attraction of neutrophils in Lupus Nephritis (LN), similar to
findings in anti-GBM disease [4–6]. Although an abundance
of autoantibodies can be detected in sera from SLE patients,
only a limited number of autoantibodies are associated with
specific disease manifestations such as anti-dsDNA and LN
[1]. In contrast, antibodies against other intracellular anti-
gens, such as anti-Ro/La, are in general consistently present
in stable titers over prolonged periods of time, independent
of underlying disease activity [7].
Copy number variation (CNV) designates the presence of
duplications or deletions of DNA segments of considerable
size (more than 1 kb) and may be present in as much of 12%
of the human genome [8, 9]. CNV is increasingly recognized
as an important genetic predisposing factor for complex
diseases including SLE and RA [10, 11]. FCGR3B is an activat-
ing membrane glycoprotein expressed specifically by human
neutrophils (and stimulated eosinophils) and preferentially
interacts with complexed IgG [12]. IgG binding initiates a
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neutrophil effector response resulting in the clearance of IC
[13, 14]. The FCGR3B gene is carried in the FCgR cluster on
chromosome 1 (1q23), and low FCGR3B CN has emerged
as a susceptibility factor for SLE in case-controls studies
with different ethnic backgrounds [15–18]. There is however
limited information on the relationship between lowFCGR3B
CN and clinical phenotypes in SLE. An association between
low FCGR3B CN and LN has been observed in Caucasian
patients as well as in experimental lupus, but several studies
have been unable to replicate these associations in Asian
or Afro-American patients [16, 18, 19]. Despite the role of
FCGR3B in clearance of immune complexes, none of these
studies have been able to demonstrate the presumed link
between low FCGR3B CN and pathogenic IgG autoantibod-
ies. Given the limited data available, we therefore investigated
the potential association between FCGR3BCNV and relevant
disease manifestations in SLE.
2. Patients and Methods
The study included 107 Caucasian SLE patients (87%
female, median age 47 years), all fulfilling 1997 ACR
criteria for SLE classification and 162 population-based
Caucasian healthy controls (53% females, median age 56
years). Patient selection, disease activity (SLEDAI-2K),
and accrued organ damage assessment (SLICC-DI) have
been detailed before [20] (see Supplementary Tables 1
and 2 in the Supplementary Material available online at
http://dx.doi.org/10.1155/2013/750814). The study was con-
ducted in accordance with the Declaration of Helsinki and
approved by the Ethics Committees, and all participants gave
written informed consent.
2.1. CN Quantification for FCGR3B Gene. Genomic DNA
was extracted from frozen PBMCs using DNeasy Mini Kit
(Qiagen, Hilden, Germany), following the manufacturer’s
instructions. Samples were quantitated using a Nanodrop
ND-1000 Spectrophotometer (NanoDrop Technologies). CN
determination was performed using 20 ng genomic DNA in
an ABI 7300 real-time PCR system using a custom TaqMan
copy number assay (Applied Biosystems, Hs04211858-cn).
Briefly, the FCGR3B primers specifically amplified FCGR3B
within intron 3, and fluorescence detection utilized a dual-
labeled FAM-MGB probe. TaqMan copy number RNase P
(Applied Biosystems, product 4403326), with a dual-labeled
VIC-TAMRA probe, was used as the reference (2CN) assay.
Duplex PCR reactions were performed in triplicate with flu-
orescence signals normalized to ROX. Each test run included
three reference samples (1, 2, and 3 FCGR3B copies) to control
for potential batch variation.
FCGR3B copy number was analyzed using Copy Caller
software (v.1.0, Applied Biosystems, USA); results were
accepted only when the calling confidence for discrete
CN assignment was >80%, and the dCq standard devia-
tion between replicates was <0.20; otherwise samples were
retested. CN assignment was compared for three different
quantitation points (Cq): (i) Ct, with auto-baselining and
0, 2 threshold, as recommended by the manufacturer; (ii)
Cy0, which is less sensitive to amplification inhibitors [2],
again estimated using autobaselined data; (iii) cpD1 (sec-
ond derivative maximum) estimated from unbaselined data
(determined from a 6-parameter log-logistic curve which
explicitly models the baseline). The Cy0 and cpD1 estimates
were determined using the R qpcR library [2, 21, 22]. The 3
quantitation points gave equivalent CN assignments. How-
ever, occasional, sporadic FAMautobaselining problemswere
observed,which if undetected, resulted in spuriously highCN
assignment. Repeat testing confirmed that the cpD1 estimate
from unbaselined data was therefore the most reliable.
The FCGR3B qPCR CNV assay was validated against
the FCGR2C/FCGR2A paralog ratio, end point, and PCR
assay [15]. As FCGR2C CN is in complete linkage with
FCGR3B CN and FCGR2A does not exhibit CNV [15, 23],
FCGR2C/FCGR2A ratio thus offers independent confirma-
tion of FCGR3B CN [15, 23]. Briefly, a single primer pair
was used to coamplify FCGR2C and FCGR2A, and the
amplicons corresponding to each gene (274 and 279 bp, resp.)
were quantified following capillary electrophoresis (QIAxcel,
USA). One hundred samples were tested in parallel for
both assays. The methodology has been described in detail
before [24]. There was complete concordance between the
independently assigned CN for the FCGR3B qPCR assay
and the FCGR2C paralog ratio end-point PCR assay for 99
samples; one sample was not assigned by the paralog ratio
method and was not retested.
2.2. Serological Assays. IgG class antibodies against double-
strandedDNA(anti-dsDNA) andRo/Lawere routinely tested
in our immunology laboratory by enzyme immunoassays
(Elia, Phadia, Freiburg, Germany), while antibody levels
against nucleosomes, C1q, and ribosomal protein P were
determined by ELISA (Orgentec Diagnostika, Mainz, Ger-
many) and BAFF by a sandwich enzyme immunoassay
(Quantikine Immunoassay; R&DSystems,Minneapolis,MN,
USA) on stored serumaliquots (−20∘C). All assays performed
in duplex following the manufacturers’ recommendations.
2.3. Statistics. Numbers represent medians unless specified
otherwise. The association between FCGR3B CN and disease
susceptibilitywas analyzed by odds ratios (OR). Comparisons
of median levels between groups were done by Mann-
Whitney U test, while Spearman’s correlation coefficient of
ranked values was used to determine the strength of relations
between continuous variables and 𝜒2 test to test associations
between discontinuous variables. Resulting 𝑃-values <0.05
were considered indicative of statistical significance. Clinical
and serological disease features associated with LN by logistic
regression analyses were subsequently entered intomultivari-
ate backward modeling based on Wald statistics (𝑃 < 0.1 to
enter) to determine their independent relationship with LN.
3. Results
The FCGR3B CN distribution (Table 1) was significantly
different in SLE patients compared to controls (𝜒2 13.8, 𝑃 =
0.001). When compared with the normal diploid 2 CN, low
Autoimmune Diseases 3
Table 1: Frequency of copy number (CN) variation in the FCGR3B
gene in SLE patients and controls. Odds ratios with 95% confidence
intervals (CI) for the association between FCGR3B gene copy









<2 20% 6% 4.15 (CI: 1.82–29.46) 𝑃 = 0.0003
2 70% 86% 1
>2 9% 8% 1.03 (CI: 0.43–2.47) 𝑃 = 0.82
Global 𝜒2 = 13.78, degrees of freedom = 2, and 𝑃 = 0.001.
FCGR3B CN (≤1) was increased in frequency in SLE (OR
4.15, 95% CI: 1.82–9.46, 𝑃 = 0.0003), while there was no
association with high FCGR3B CN (≥3, 𝑃 = 0.82) (Table 1).
Within the SLE cohort, low FCGR3B CN was associated
with higher SLEDAI-2K scores (𝑃 = 0.03, Table 2). Low
FCGR3BCNwas also increased in frequency in patients with
active renal disease (characterized by proteinuria with active
urinary sediment) (25 versus 6.4%, 𝑃 = 0.03) (Table 2). Low
FCGR3B CN was not associated with onset age or gender,
arthritis, skin disease or other manifestation of active disease
as defined in SLEDAI-2K, total or organ system-specific
scores SDI scores.
In terms of serological/laboratory findings, low FCGR3B
CN was associated with a higher prevalence and increased
levels of anti-dsDNA, anti-C1q, and antiribosomal P autoan-
tibodies (Table 2). FCGR3B CN was however unrelated to
anti-Ro prevalence, RF titers, ESR, hemoglobin leukocyte
or lymphocyte counts, C3, and s-BAFF levels (data not
shown). In nonparametric correlation analyses, FCGR3B CN
was inversely and significantly correlated with anti-dsDNA
(Rs −0.24; 𝑃 = 0.015), antiribosomal P (Rs −0.31; 𝑃 =
0.002), and anti-C1q (Rs −0.251; 𝑃 = 0.01) autoantibody
titers, but not to RF (Rs 0.12; 𝑃 > 0.3). Upon multivariate
logistic regression analysis, the final model confirmed an
independent relation with LN for anti-C1q antibody levels
(OR 1.03, 𝑃 = 0.026), while the relation with low FCGR3B
CN reached only borderline statistical significance despite its
large effect size effect (OR 4.2, 𝑃 = 0.09) (Table 3).
4. Discussion
FCGR3B is a stimulatory receptor located predominantly on
the cell surface of neutrophils and belongs to the family
of Fc gamma receptors, which are primarily involved in IC
clearance [13]. This study confirms that low FCGR3B CN is
a susceptibility factor for SLE [13, 14, 17–19]. In addition, we
show for the first time a link between low FCGR3B CN and
the presence and titers of specific pathogenic autoantibodies
in SLE.
FCGR3B CN variation has become established as a risk
factor for a range of systemic autoimmune diseases, including
RA, Sjo¨gren’s syndrome, and SLE [11]. This reflects a growing
realization that CNV is frequent throughout the genome and
may be important genetic risk factors for complex disease
[9, 25, 26]. The observed effect size for this association
(OR 4.2) was larger than in previously reported studies but
falls within the confidence interval reported in a recent meta-
analysis [11].
While the association between low FCGR3B CN and
SLE susceptibility is firmly established, there is still limited
knowledge about the mechanism by which FCGR3B CN
contributes to this disease [1, 27]. Our data support an
association between low FCGR3B CN and the prevalence
of LN in Caucasian patients, while no such association has
been observed in in Chinese and Hispanic patients [16, 19,
28]. Other studies have demonstrated that single nucleotide
polymorphisms (SNPs), but not CNV of the FCGR3B gene,
constituted a risk factor for LN in Chinese and other SLE
cohorts [12, 25, 28]. Morris et al. have shown that there is
a combined effect of FCGR3B CNV and the presence of
NA1/NA2 SNP on disease susceptibility [29], and it is clearly
of interest to further investigate how combined changes in
FCGR3B gene copy number and product structure impact on
disease susceptibility and clinical phenotypes.
Low FCGR3B CN was not associated with any other
clinical manifestation of SLE in this study and other studies
[16, 19, 28]. The association with higher SLEDAI scores is
likely a reflection of the higher scores obtained by patients
with LN.
The biological role of FCGR3B is not fully elucidated.
FCGR3B lacks a transmembrane domain and must interact
with other membrane receptors such as FCGR2A and 𝛽2-
integrin (CD11/CD18b) to fully activate neutrophils [30–32].
In vitro cross-linking of FCGR3B induces calcium mobiliza-
tion and tyrosine phosphorylation and leads to tethering of
neutrophils to immobilized ICs and IgG phagocytosis [31,
33, 34]. In healthy controls, low FCGR3B CN reduces the
adherence of neutrophils to IC and subsequent IC clearance
[35], and it seems reasonable to assume a similar effect in
SLE patients. The anticipated consequence would be higher
levels of circulating IC/autoantibodies, but this has not been
documented in human SLE. This study is one of the first to
demonstrate a link between low FCGR3B CN and high titers
of antibodies against dsDNA, C1q, and ribosomal protein P
in SLE patients. These autoantibodies are among the most
disease-specific autoantibodies in SLE, and in particular, anti-
dsDNAand anti-C1q are implicated in the pathogenesis of LN
[1, 36]. Our data suggest that these circulating autoantibodies
represent a potential connection between low FCGR3B CN
and human lupus, especially LN [19, 37].
Antibodies against Ro/La, Sm, and IgG (RF) were not
associated with variation in FCGR3B CN in this SLE cohort.
Compared to anti-dsDNA and anti-C1q autoantibodies, both
RF and anti-Ro/La are less disease specific and do not
fluctuatewith disease activity [1]. RF exerts a differential effect
on IC clearance, and depending on characteristics such as
antibody excess and glycosylation of the Fc fragment may
increase or decrease IC uptake [32, 38]. Data from RA studies
have also failed to show a convincing association between
low FCGR3B CN and RF or antibodies against citrullinated
peptides (ACPA) [24, 39], while studies in Sjo¨gren’s syndrome
patients failed to find an association with anti-Ro antibodies
[40, 41]. An association between renal disease and anti-Sm
has been described in African-American SLE patients who
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Table 2: Univariate analysis comparing clinical features between SLE patients with low (<2) FCGR3B and ≥2 FCGR3B gene copy number.
Figures indicate mean values or number of patients (percentage). 𝑃 values derive from Mann-Whitney U test and chi-square testing as
appropriate.
FCGR3B < 2 (𝑛 = 21) FCGR3B ≥ 2 (𝑛 = 86) 𝑃 value
Age (yrs) 43.3 47.9 0.3
Female gender (%) 18 (86) 77 (90) 0.47
Disease duration (months) 162 151 0.7
Organ damage present (SDI > 0) 60 58 0.9
SLEDAI-2K score 10.4 6.1 0.03
LN present (%) 5 (24) 6 (6.9) 0.03
Arthritis present (%) 4 (19) 9 (11) 0.3
Active skin lesions present (%) 2 (10) 3 (4) 0.4
Leukocytopenia (<4) 3 (14) 18 (21) 0.3
Anti-dsDNA positive 8 (38) 16 (18) 0.05
Anti-dsDNA titer (𝑛 < 55 IU) 81 37 0.03
Anti-C1q positive 6 (29) 10 (12) 0.06
Anti-C1q titer (𝑛 < 11 IU) 22 5.5 0.003
Antiribosomal P positive 4 (19) 6 (7) 0.1
Antiribosomal P titer (𝑛 < 8 IU) 10 5 0.01
Anti-Ro positive (%) 43 36 0.62
Anti-Sm positive (%) 5 6 0.9
Low C3 (<81mg/dL) (%) 30 28 0.9
SLEDAI-2K: SLE Disease Activity Index-2000 version, SDI: SLICC-ACRDamage Index, LN: lupus nephritis (see methods for definition), and C3: complement
factor 3.
Table 3: Odds ratios (OR) for the association between disease characteristics and presence of LN. OR correspond to Exp (𝛽) in
logistic regression analyses with presence of active LN as the dependent parameter (see methods for detailed description). “—” indicates
nonsignificant findings upon multivariate analysis.
Univariate Multivariate
Exp (𝛽) CI 𝑃 value Exp (𝛽) CI 𝑃 value
FCGR3B CN < 2 4.8 1.25–18.9 0.02 4.2 0.8–23.6 0.09
Serum albumin 0.87 0.77–0.99 0.047 — — —
Anti-dsDNA Ab 1.01 1.003–1.018 0.008 — — —
Anti-C1q Ab 1.04 1.01–1.06 0.003 1.03 1.03–1.05 0.026
Low C3 7.1 1.6–29.8 0.007 — — —
tend to have a fourfold higher prevalence of anti-Sm than
Caucasian patients [42]. The distribution of anti-Sm was
similar between patients with low or high FCGR3B CN as
was otherwise the case for other antibodies against ENA,
which all have a less distinctive association with clinical
disease. While a potential role for FCGR3B CNV and anti-
Sm could not be substantiated in this Caucasian cohort, this
does not exclude a potential association in other cohorts.
Together, these data indicate that the specificity of an anti-
body is of major importance in the interaction with FCGR3B,
and more detailed study of the functional consequences of
FCGR3B stimulation by SLE-specific (complexed as well as
monomeric) autoantibodies will be highly informative.
The strength of this study lies in the integrated approach
formeasuringCNvariation that included extensive data qual-
ity checking as well as independent validation by a separate
assay. This methodology resulted in high confidence and
discrete CN calls which have emerged as important aspect
of FCGR3B CNV determination [11, 43]. Nonetheless, every
method for CNV study presents its own unique challenges
making direct comparisons difficult, especially given with
regards to the newer microarray-based technologies [25].
Another asset of this study is the uniformity of data
ensured by simultaneous collection of clinical and laboratory
data in a genetically homogenous cohort from a single centre
and subsequent uniform ELISA-based testing of expanded
autoantibody profiles. The main limitation of this study is
the moderate cohort size. While a larger sample size would
have increased the power of our findings, it would not be
anticipated to effectively change the results as sample size was
not widely different from other studies where the impact of
FCGR3B CNV on disease susceptibility was described [24,
41]. Also, serological data on circulating immune complexes
(CIC) were not available as CIC measurement is no longer
routinely practiced. CIC assays do not provide insight into the
specificity of the antigen-antibody interaction [44, 45]. Par-
ticularly important, CIC assays do not differentiate antigen-
complexed antibody from non-specifically aggregated or
Autoimmune Diseases 5
monomeric autoantibody asC1qBA results are confounded by
monomeric immunoglobulin such as anti-C1q in serum of
SLE patients [46].
5. Conclusions
We confirm that low FCGR3B CN is a risk factor for LN in
Caucasian SLE patients, likely through a selective reduction
in the clearance of disease-specific autoantibodies only. This
suggests that FCGR3B is involved in removal of a limited
repertoire of pathogenic autoantibodies in SLE.
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